Pain, PostoperativeOrthognathic SurgeryOpioid UsePatient SatisfactionOpioid Use Disorder
Investigational drug(s) / intervention(s)
Personalization of dose and frequency and instituting a tapering protocol of hydromorphone post-orthognathic surgeryStandardized dose and frequency of hydromorphone with no tapering post-orthognathic surgery
Personalization of dose and frequency and instituting a tapering protocol of hydromorphone post-orthognathic surgery: POP participants will be given a personalized opioid prescription with a tapering protocol based on their last inpatient 24-hour usage of opioids, obtained from the nursing medication administration record. Should a participant stay in the hospital for less than 24 hours (e.g. patient had an early discharge at 18 hours), the 24-hour in-patient opioid usage would be extrapolated from their total amount and frequency of opioid use. The participant will be provided with an instruction card with suggestions on how much opioid to take at various time points following discharge to safely taper their medication.
Standardized dose and frequency of hydromorphone with no tapering post-orthognathic surgery: SOP participants will be given a standardized dose of hydromorphone (2-4mg orally every 6 hours), and a total amount of 40mg. No further information is provided to them with regards to their pain medication and to tapering.
Study summary
This study aims to investigate pain management and satisfaction following orthognathic surgery, which is a type of surgery that corrects jaw and facial bone issues. This type of surgery can result in significant post-operative pain for participants, and the goal of this study is to find a way to manage this pain in a more effective and safe manner.
The study will focus on the use of opioid pain medication and will compare two groups: one group will receive a standardized prescription plan. In contrast, the other group will receive a personalized prescription with a plan to taper the opioid medication. In the end, any unused opioid will be compared at the end of the 7-day post-discharge period between the two groups. This is important because excessive opioid prescription can either be diverted to the community or can be misused leading to opioid use disorders.
Data will be collected from pre-surgery appointments, during the surgery and hospital stay, and follow-up appointments. The data collected will include participants' demographics, medical history, type of surgery, and information about the pain medication used.
The study hypothesizes that the personalized prescription plan will result in less unused medication and higher satisfaction with pain management compared to the standardized prescription plan. The study will also stratify the participants into single-jaw surgery and double-jaw surgery groups to evaluate if any differences in the outcomes are observed. This study will help to provide guidance for future pain management practices for participants undergoing orthognathic surgery. Furthermore, this study will also benefit society by providing insights into addressing the opioid crisis that is currently affecting many communities across North America.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion criteria
1. Patients undergoing orthognathic surgery for the correction of dentofacial deformities. Included in the study will be patients who receive single-jaw surgery (i.e. BSSO \[Bilateral Sagittal Split Osteotomy, a surgery of the lower jaw\] only, or Lefort \[osteotomy of the upper jaw\] only), or those in the double-jaw surgery category (BSSO and Lefort).
2. Patients undergoing a functional genioplasty who have an additional osteotomy included in their surgical plan (i.e. BSSO and/or Lefort).
3. Patients undergoing cleft orthognathic surgery.
Exclusion criteria
1. Patients who are under the age of 18 at the time of surgery
2. Patients who are contraindicated to undergo elective surgery, including pregnant patients.
3. Patients with a history of opioid use disorder.
4. Patients on chronic opioids within the past month.
5. Patients who have a contraindication for multimodal analgesia (e.g. renal injury precluding the prescription of NSAIDs).
6. Patients with allergies to opioids, acetaminophen, and/or NSAIDs.
7. Patients receiving a surgically-assisted rapid palatal expansion (SARPE) surgery due to the different post-operative nature of the surgery.
8. Patients who have previously undergone prior orthognathic (i.e. repeat surgery), non-cleft craniofacial surgery, or have previously experienced maxillofacial trauma due to the potential alterations in neural pain pathways.
9. Patients undergoing an isolated functional genioplasty.
10. Patients who are unable to consent to surgery and/or the study.
Primary outcome measure(s)
Fraction (%) of remaining unused opioid — Assessed at 7-days post-discharge, which is the point at which participant would have completed their post-operative recovery period and are expected to have ceased using their prescribed opioid medication. The participant will self-report how much liquid hydromorphone (1mg/mL) remains in millilitres after they have stopped consuming it for management of their acute post-surgical pain, expected to be at 7-days post-op. The participant will also bring their remaining opioid to their first follow-up appointment to confirm this measurement.
The remaining opioid is compared to their prescribed opioid to determine the relative amount of unused opioid measured as a percentage.
Absolute amount (milligrams) of remaining unused opioid — Assessed at 7-days post-discharge, which is the point at which participant would have completed their post-operative recovery period and are expected to have ceased using their prescribed opioid medication. The participant will self-report how much liquid hydromorphone (1mg/mL) remains in millilitres after they have stopped consuming it for management of their acute post-surgical pain, expected to be at 7-days post-op. The participant will also bring their remaining opioid to their first follow-up appointment to confirm this measurement.
The remaining opioid is compared to their prescribed opioid to determine the absolute amount of unused opioid measured in milligrams.
Trial sites (1)
Facility
City
Region
Status
Dalhousie University
Halifax
Nova Scotia
More Nova Scotia Health Authority trials in Canada
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.